Article Text

Download PDFPDF

182 Highly potent fully human anti-VISTA antibodies – a new target checkpoint inhibitor against immunosuppressive myeloid cells
  1. Thierry Guillaudeux,
  2. Eric Tarcha,
  3. Robert Bader,
  4. Benjamin Dutzar,
  5. Nathan Eyde,
  6. Emily Frazier,
  7. David Jurchen,
  8. Remington Lance,
  9. Cristina Loomis,
  10. Kurt Lustig,
  11. Yulia Ovechkina,
  12. David Peckham,
  13. Shaarwari Sridhar,
  14. Mei Xu,
  15. Shawn Iadonato,
  16. Thierry Guillaudeux and
  17. Jeff Posakony
  1. Kineta Inc., Seattle, WA, USA


Background V-domain Immunoglobulin Suppressor of T cell Activation (VISTA/PD-1H) is a B7 family ligand expressed on circulating and intratumoural myeloid cells as well as Treg and NK cells. It has been shown to inhibit T cell responses in vitro and in preclinical models. In patients, VISTA is also a potential mediator of resistance to anti-CTLA-4 and anti-PD1 therapies and therefore is a valuable new target for cancer immunotherapy.

Methods Kineta has analyzed 107 fully human ScFv antibodies directed against VISTA.

Results Our lead candidates exhibit high potencies in the subnanomolar range and are also characterized by a long kDis. They specifically target human and cynomolgus monkey VISTA on a singular unique epitope. In a Staphylococcus Enterotoxin B T-cell activation assay, Kineta’s anti-VISTA antibodies efficiently induce IFNg secretion. They also promote strong maturation of Antigen Presenting Cells with an increase of CD80 and HLA-DR surface expression as well as CXCL10 secretion. The mechanism of action is mediated in part by NK cells. We demonstrated that myeloid cells acquire a high level of VISTA expression during MDSC or M2 differentiation in vitro and that Kineta’s anti-VISTA antibodies prevent the differentiation of MDSC as well as their immunosuppressive activity against T cells. Anti-VISTA antibodies mediate single-agent antitumor effects in syngeneic tumor models in wild-type mice and show enhanced activity in combination with anti-PD1 and anti-CTLA-4 treatment. Candidate anti-VISTA antibodies have also been evaluated in exploratory tolerability and PK studies in cynomolgus monkey. These studies demonstrated that multiple weekly doses of antibodies are well-tolerated with appropriate PK for lead selection and optimization.

Conclusions Our results strongly favor further characterization and continued development of selected lead antibodies for the potential treatment of colder, less immunogenic tumors.

Ethics Approval Study approved by the Institutional Animal Care and Use Committee PHS Assurance # D16-00885 and D16-00114

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.